OMB and DoL Direct Agencies to Appoint Labor Compliance Advisors Pursuant to "Fair Pay" EO
Client Alert | 1 min read | 03.09.15
On March 5, OMB and DoL circulated a Memorandum to federal agencies regarding the "Fair Pay and Safe Workplaces" Executive Order (previously discussed here, and here), providing "guidance" with respect to the Labor Compliance Advisor role created by the EO, and directing agencies to designate within 90 days a senior-level official to serve as LCA. The memo, which reiterates the troubling scope and nature of the new position (i.e., "providing assistance to contracting officers" during the procurement process, "advising … contracting officers and other agency officials regarding recommended actions to be taken in response to labor law violations," and "sending any relevant information to suspending and debarring officials"), also states that GSA will create a new web site for the labor compliance reporting requirements identified in the EO, and indicates that FAR Council regulatory action and additional DoL guidance will be forthcoming.
Contacts
Insights
Client Alert | 8 min read | 06.30.25
AI Companies Prevail in Path-Breaking Decisions on Fair Use
Last week, artificial intelligence companies won two significant copyright infringement lawsuits brought by copyright holders, marking an important milestone in the development of the law around AI. These decisions – Bartz v. Anthropic and Kadrey v. Meta (decided on June 23 and 25, 2025, respectively), along with a February 2025 decision in Thomson Reuters v. ROSS Intelligence – suggest that AI companies have plausible defenses to the intellectual property claims that have dogged them since generative AI technologies became widely available several years ago. Whether AI companies can, in all cases, successfully assert that their use of copyrighted content is “fair” will depend on their circumstances and further development of the law by the courts and Congress.
Client Alert | 3 min read | 06.30.25
Client Alert | 3 min read | 06.26.25
FDA Targets Gene Editing Clinical Trials in China and other “Hostile Countries”
Client Alert | 3 min read | 06.26.25
